A Phase 3 interventional study of ertapenem sodium and ceftriaxone sodium in Infection and Surgical Site Infection, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-03-22.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the efficacy and safety of ertapenem sodium compared with ceftriaxone sodium/metronidazole for the prophylaxis of surgical site infection following elective colorectal surgery in Chinese adults. This study is designed to demonstrate that ertapenem sodium is non-inferior to ceftriaxone sodium/metronidazole in this participant population.
747 studies on the registry are indexed under Surgical Wound Infection; 152 are open to participants now.
This study's enrollment of 599 is above the median of 200 across 583 interventional studies indexed under Surgical Wound Infection.
Browse Surgical Wound Infection studies →Merck Sharp & Dohme LLC is the lead sponsor of 2,169 studies on the registry; 134 are open to participants now.
Of its 505 completed or terminated interventional studies of FDA-regulated products, 372 (74%) have results posted.
Compared within Surgical Wound Infection, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
laparotomy that is scheduled in advance with adequate time prior to surgery to
complete preoperative bowel preparation.
less than 81 years old.
Exclusion Criteria:
ulcerative colitis or Crohn's disease).
immunosuppressive therapy, or use of high-dose .
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ertapenem sodium 1 g administered intravenously (IV) as a single dose followed by matching placebo to metronidazole administered IV as a single dose
Drug: ertapenem sodium · Drug: placebo to metronidazole
Ceftriaxone sodium 2 g administered intravenously (IV) as a single dose followed by metronidazole 500 mg administered IV as a single dose
Drug: ceftriaxone sodium · Drug: metronidazole
Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
Also known as: MK-0826, INVANZ®
Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
Also known as: Rocephin®
Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
Also known as: Flagyl®
Percentage of Participants With Success of Prophylaxis
Percentage of participants who have no signs or symptoms of infection at the surgical site, do not require surgical intervention for infection, and have no need for further antimicrobial therapy
Time frame: From study drug dose (day of surgery) up to 4 weeks post therapy
Percentage of Participants With Favorable Clinical Response
Percentage of participants who have no signs or symptoms of infection at the surgical site and do not require surgical intervention for infection
Time frame: 4 weeks posttreatment
| Milestone | Ertapenem | Ceftriaxone/Metronidazole |
|---|---|---|
| Started | 299 | 300 |
| Treated | 290 | 297 |
| Completed | 286 | 281 |
| Not completed | 13 | 19 |
| Withdrew: Adverse event | 2 | 5 |
| Withdrew: Physician decision | 7 | 4 |
| Withdrew: Protocol violation | 1 | 4 |
| Withdrew: Withdrawal by subject | 3 | 6 |
Percentage of participants who have no signs or symptoms of infection at the surgical site, do not require surgical intervention for infection, and have no need for further antimicrobial therapy
| percentage of participants | Ertapenem | Ceftriaxone/Metronidazole |
|---|---|---|
| Percentage of Participants With Success of Prophylaxis | 90.4 (86.8 to 94.1) | 90.3 (86.6 to 94.0) |
Percentage of participants who have no signs or symptoms of infection at the surgical site and do not require surgical intervention for infection
| percentage of participants | Ertapenem | Ceftriaxone/Metronidazole |
|---|---|---|
| Percentage of Participants With Favorable Clinical Response | 96.8 (94.6 to 99.0) | 95.5 (93.0 to 98.1) |
Collected over Up to and including 28 days after last administration of study drug. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ertapenem | — | 6/290 (2.1%) | 23/290 (7.9%) |
| Ceftriaxone/Metronidazole | — | 14/297 (4.7%) | 18/297 (6.1%) |
| Event | Ertapenem | Ceftriaxone/Metronidazole |
|---|---|---|
| Anastomotic LeakInjury, poisoning and procedural complications | 3/290 | 1/297 |
| Wound DehiscenceInjury, poisoning and procedural complications | 0/290 | 2/297 |
| Intestinal ObstructionGastrointestinal disorders | 1/290 | 0/297 |
| Anastomotic FistulaInjury, poisoning and procedural complications | 1/290 | 1/297 |
| Post Procedural HaemorrhageInjury, poisoning and procedural complications | 1/290 | 0/297 |
| Cardiac ArrestCardiac disorders | 0/290 | 1/297 |
| Cardiac Failure AcuteCardiac disorders | 0/290 | 1/297 |
| VomitingGastrointestinal disorders | 0/290 | 1/297 |
| CholecystitisHepatobiliary disorders | 0/290 | 1/297 |
| Cholecystitis AcuteHepatobiliary disorders | 0/290 | 1/297 |
| Event | Ertapenem | Ceftriaxone/Metronidazole |
|---|---|---|
| PyrexiaGeneral disorders | 23/290 | 18/297 |
| Age, Continuous(years) | Ertapenem | Ceftriaxone/Metronidazole | Total |
|---|---|---|---|
| Mean | 59.4 ± 11.4 | 59.1 ± 12.1 | 59.2 ± 11.8 |
| Sex: Female, Male(Participants) | Ertapenem | Ceftriaxone/Metronidazole | Total |
|---|---|---|---|
| Female | 125 | 127 | 252 |
| Male | 165 | 170 | 335 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
The record gives a start of Dec 2010, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2012, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ertapenem